Cellectis S.A.
CLLSAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 16, 2026 | Barclays | Lukas Shumway | $1.30(-19%) | $1.61 | StreetInsider |
| Sep 15, 2026 | Wells Fargo | Nick Abbott | $3.00(+64%) | $1.83 | TheFly |
| May 28, 2026 | Barclays | Lukas Shumway | $9.00(+148%) | $3.63 | StreetInsider |
| Oct 20, 2025 | Wells Fargo | Nick Abbott | $4.00(+1%) | $3.98 | TheFly |
| Oct 17, 2025 | Barclays | Gena Wang | $8.00(+77%) | $4.52 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Barclays | downgrade | Overweight →Underweight | Sep 16, 2026 |
| Wells Fargo | maintain | Equal Weight | Sep 15, 2026 |
| Citizens | downgrade | Market Outperform →Market Perform | Sep 15, 2026 |
| Baird | maintain | Outperform | Sep 15, 2026 |
| Citizens | maintain | Market Outperform | Apr 14, 2026 |
| Barclays | maintain | Overweight | Oct 17, 2025 |
| Barclays | maintain | Overweight | May 13, 2025 |
| Barclays | maintain | Overweight | Nov 5, 2024 |
| Oppenheimer | maintain | Outperform | Jun 12, 2024 |
| JMP Securities | maintain | Market Outperform | May 31, 2024 |
| JMP Securities | maintain | Market Outperform | Nov 1, 2023 |
| Oppenheimer | maintain | Outperform | Aug 8, 2023 |
| JMP Securities | maintain | Market Outperform | Aug 7, 2023 |
| Citigroup | maintain | Buy | Apr 5, 2023 |
| Oppenheimer | maintain | Outperform | Mar 13, 2023 |
| JMP Securities | maintain | Market Outperform →Outperform | Mar 13, 2023 |
| JMP Securities | maintain | Market Outperform | Jan 19, 2023 |
| Goldman Sachs | maintain | Sell | May 24, 2022 |
| Baird | upgrade | Neutral →Outperform | May 18, 2022 |
| Barclays | maintain | Overweight | May 13, 2022 |
| Wells Fargo | downgrade | Overweight →Equal Weight | Jan 6, 2022 |
| JMP Securities | maintain | Market Outperform →Outperform | Nov 30, 2021 |
| Baird | downgrade | Outperform →Neutral | Oct 8, 2021 |
| Guggenheim | downgrade | Buy →Neutral | Apr 28, 2021 |
| Baird | upgrade | Neutral →Outperform | Mar 16, 2021 |
Earnings History
Next report: Nov 13, 2026 · EPS est. $-0.18| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 6, 2026 | $-0.22 | $-0.26 | $6.9M | $11.0M |
| May 11, 2026 | $-0.18 | $-0.26 | $7.5M | $11.0M |
| Mar 19, 2026 | $-0.26 | $-0.20 | $12.2M | $13.4M |
| Nov 7, 2025 | $0.01 | $-0.10 | $35.2M | $10.3M |
| Aug 4, 2025 | $-0.24 | $-0.10 | $16.9M | $8.2M |
| May 12, 2025 | $-0.18 | $-0.19 | $10.7M | $12.7M |
| Mar 13, 2025 | $-0.16 | $0.06 | $12.7M | $9.2M |
| Nov 4, 2024 | $-0.23 | $-0.20 | $16.2M | $20.4M |
News
Un taux d'édition in vivo du gène APOC3 humain atteignant 70% après une seule administration Une réduction de 76 % du taux de triglycérides après une dose unique dans un modèle murin de la maladie NEW YORK, 27 oct.
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment, today announced the presentation of preclinical data supporting .HEAL-101, its in vivo base editing product candidate targeting APOC3 for severe hypertriglyceridemia (sHTG), at the Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), being held October 27-30, 2026, in H…
NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ: CLLS).
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
LOS ANGELES, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS) investors concerning the Company's possible violations of the federal securities laws.
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ: CLLS).
BENSALEM, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G.
LOS ANGELES, Oct. 14, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS) on behalf of investors concerning the Company's possible violations of federal securities laws.
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ: CLLS).
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
Cellectis NASDAQ: CLLS outlined plans to advance two preclinical in vivo gene-editing candidates for severe forms of dyslipidemia, targeting hypertriglyceridemia and hypercholesterolemia through one-time intravenous treatments.
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ: CLLS).
Cellectis S.A. (NASDAQ: CLLS - Get Free Report) has received an average rating of "Hold" from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, two have given a hold rating, two have given a buy rating and one has given a
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A.
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
LOS ANGELES--(BUSINESS WIRE)---- $CLLS--CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law.